Patents Assigned to MSD Oss B.V.
-
Patent number: 9505802Abstract: The present invention relates to a method for the isolation of proteins that comprise disulfide-bonds in their native conformation. Essentially, a method of the present makes the use of reducing agents such as ?-mercaptoethanol or dithiothreitol in protein isolation methods obsolete. A method of the present invention is particularly suitable for the isolation of precursor proteins such as proinsulin from recombinant cells.Type: GrantFiled: July 8, 2014Date of Patent: November 29, 2016Assignee: MSD OSS B.V.Inventors: Peter Van Der Meijden, Gijsbert Willem Karel Van Dedem, Michel Hendrikus Maria Eppink, Roeland Wilhelmus Wassenaar
-
Patent number: 8802395Abstract: The present invention relates to a method for the isolation of proteins that comprise disulfide bonds in their native conformation. Essentially, a method of the present invention makes use of reducing agents such as ?-mercaptoethanol or dithiothreitol in protein isolation methods obsolete. A method of the present invention is particularly suitable for the isolation of precursor proteins such as proinsulin from recombinant cells.Type: GrantFiled: May 9, 2012Date of Patent: August 12, 2014Assignee: MSD OSS B.V.Inventors: Peter Van Der Meijden, Gijsbert Willem Karel Van Dedem, Michel Hendrikus Maria Eppink, Roeland Wilhelmus Wassenaar
-
Publication number: 20130131029Abstract: The present invention relates to a antisolvent solidification process wherein a liquid medium comprising at least one organic or inorganic compound which is to be solidified is forced through a membrane into one or more antisolvents, or wherein one or more antisolvents are forced through a membrane into a liquid medium comprising at least one organic or inorganic compound which is to be solidified, yielding a composition comprising solid particles comprising said organic and/or inorganic compound(s).Type: ApplicationFiled: January 9, 2013Publication date: May 23, 2013Applicant: MSD Oss B.V.Inventor: MSD Oss B.V.
-
Publication number: 20130115265Abstract: The subject invention provides a drug delivery system comprising at least one compartment consisting of (i) a drug-loaded thermoplastic polymer core, (ii) a drug-loaded thermoplastic polymer intermediate layer and (iii) a non-medicated thermoplastic polymer skin covering the intermediate layer, wherein said intermediate layer is loaded with (a) crystals of a first pharmaceutically active compound and with (b) a second pharmaceutically active compound in dissolved form and wherein said core is loaded with said second compound in dissolved form.Type: ApplicationFiled: November 9, 2012Publication date: May 9, 2013Applicant: MSD Oss B.V.Inventor: MSD Oss B.V.
-
Publication number: 20130108651Abstract: Antibodies which block binding of hPD-1 to hPD-L1 or hPD-L2 and their variable region sequences are disclosed. A method of increasing the activity (or reducing downmodulation) of an immune cell through the PD-1 pathway is also disclosed.Type: ApplicationFiled: December 19, 2012Publication date: May 2, 2013Applicant: MSD OSS B.V.Inventor: MSD OSS B.V.
-
Publication number: 20130078286Abstract: The subject invention provides a drug delivery system comprising at least one compartment consisting of (i) a drug-loaded thermoplastic polymer core, (ii) a drug-loaded thermoplastic polymer intermediate layer and (iii) a non-medicated thermoplastic polymer skin covering the intermediate layer, wherein said intermediate layer is loaded with (a) crystals of a first pharmaceutically active compound and with (b) a second pharmaceutically active compound in dissolved form and wherein said core is loaded with said second compound in dissolved form.Type: ApplicationFiled: November 9, 2012Publication date: March 28, 2013Applicant: MSD Oss B.V.Inventor: MSD Oss B.V.
-
Patent number: 8394789Abstract: The invention relates to 5,6-dihydropyrrolo[2,1-?]isoquinoline and pyrrolo[2,1-?]isoquinoline derivatives according to general formula (I) or a pharmaceutically acceptable salt thereof. The compounds can be used for the treatment of infertility.Type: GrantFiled: February 6, 2009Date of Patent: March 12, 2013Assignee: MSD Oss B.V.Inventors: Rachel Deborah van Rijn, Hubert Jan Josef Loozen, Cornelis Marius Timmers, Lars Anders van der Veen, Willem Frederik Johan Karstens
-
Patent number: 8367648Abstract: The present invention relates to substituted steroid compounds having the formula Wherein R1 is H or halogen; R2 is H, (1C-4C)alkyl, (1C-4C)acyl, glucuronyl or sulfamoyl; R3 is H or halogen; R4 is H, (1C-4C)alkyl, (2C-4C)alkenyl or (2C-4C)alkynyl; R5 is methyl or ethyl; R6 is H or methyl; R7 is H or methyl; R8 is H or acyl for use in the treatment and prevention of endometriosis, for contraception, for hormonal therapy in perimenopausal and post-menopausal women, for the treatment of osteoporosis and for the treatment uterine fibroids and other menstrual-related disorders, such as dysfunctional uterine bleeding.Type: GrantFiled: June 8, 2010Date of Patent: February 5, 2013Assignee: MSD OSS B.V.Inventors: Fredericus Antonius Dijcks, Hubert Jan Jozef Loozen, Samira Addo, Antonius Gerardus Hendrikus Ederveen
-
Patent number: 8357679Abstract: The present invention relates to hexafluoroisopropanol derivatives having the general formula I to pharmaceutical compositions comprising the same and to the use of these hexafluoroisopropanol derivatives in the treatment of atherosclerosis.Type: GrantFiled: May 13, 2009Date of Patent: January 22, 2013Assignee: MSD Oss B.V.Inventors: Andrew John Cooke, Andrew Stanley Edwards, Fiona Elizabeth Andrews, David Jonathan Bennett, Olaf Nimz, Emma Louise Carswell
-
Publication number: 20130014763Abstract: An intrauterine system for the retention of a biologically active compound within the uterus of a female mammal is formed by a frame defining an interior space for receipt of a deposit of the compound. The frame has an open structure allowing access to a substantial part of an outer surface of the deposit and the deposit has a rate controlling structure that controls a rate of release of the compound within the uterus. Retention elements are provided on the frame for retaining the frame within the uterus.Type: ApplicationFiled: September 18, 2012Publication date: January 17, 2013Applicant: MSD Oss B.V.Inventors: Wouter de Graaff, Harm Veenstra, Titia Martine Truce Mulders
-
Patent number: 8354509Abstract: Antibodies which block the binding of human Programmed Death Receptor 1 (hPD-1) to its ligands (hPD-L1 or hPD-L2) and their variable region sequences are disclosed. A method of increasing the activity (or reducing downmodulation) of an immune response through the PD-I pathway is also disclosed.Type: GrantFiled: June 13, 2008Date of Patent: January 15, 2013Assignee: MSD Oss B.V.Inventors: Gregory John Carven, Hans van Eenennaam, Gradus Johannes Dulos
-
Patent number: 8333983Abstract: The subject invention provides a drug delivery system comprising at least one compartment consisting of (i) a drug-loaded thermoplastic polymer core, (ii) a drug-loaded thermoplastic polymer intermediate layer and (iii) a non-medicated thermoplastic polymer skin covering the intermediate layer, wherein said intermediate layer is loaded with (a) crystals of a first pharmaceutically active compound and with (b) a second pharmaceutically active compound in dissolved form and wherein said core is loaded with said second compound in dissolved form.Type: GrantFiled: May 19, 2004Date of Patent: December 18, 2012Assignee: MSD Oss B.V.Inventors: Rudolf Johannes Joseph Groenewegen, Wouter De Graaff, Henk Jan Out
-
Patent number: 8314091Abstract: The present invention relates to N-benzyl,N?-arylcarbonylpiperazine derivatives having the general formula I to pharmaceutical compositions comprising the same, and to the use of a these N-benzyl,N?-arylcarbonylpiperazine derivatives for the manufacture of a medicament for treating or preventing atherosclerosis and related disorders associated with cholesterol and bile acids transport and metabolism.Type: GrantFiled: August 19, 2008Date of Patent: November 20, 2012Assignees: MSD OSS B.V., Pharmacopeia, Inc.Inventors: Koc-Kan Ho, Andrew Laird Roughton, Irina Neagu, Jui-Hsiang Chan, Nasrin Ansari, Michelle Lee Morris, Yajing Rong, Michael Ohlmeyer, Andrew John Cooke, Andrew Stanley Edwards, David Jonathan Bennett
-
Publication number: 20120283239Abstract: The invention relates to 1H-[1,2,3]triazolo[4,5-c]pyridine-4-carbonitrile derived Cathepsin S inhibitors of Formula (I), wherein R1 is H or (C1-3)alkyl; R2 is halogen or (C1-4)alkyl, optionally substituted with one or more halogens; n is 1-3; X is O or CH2; U, V and W are CH; or one of U, V and W is N; Y is a group capable of interacting with the Sn . . . S2 substites of the active site of Cathepsin S; or a pharmaceutically acceptable salt thereof, to pharmaceutical compositions comprising the same as well as to the use of these derivatives for the preparation of a medicament for the treatment of cathepsin S related diseases such as atherosclerosis, obesity, inflammation and immune disorders, such as rheumatoid arthritis, psoriasis, cancer, and chronic pain, such as neuropathic pain.Type: ApplicationFiled: January 13, 2011Publication date: November 8, 2012Applicant: MSD OSS B.V.Inventors: Jiaqiang Cai, David Jonathan Bennett, Philip Stephen Jones
-
Patent number: 8299091Abstract: The invention relates to the compound N-(2-oxo-2-propoxyethyl)-?-phenyl-D-phenyl-alanyl-N-[(1-amino-6-iso-quinolinyl)methyl]-L-prolinamide or a pharmaceutically acceptable salt thereof, to a pharmaceutical composition comprising said compound, as well as to the use of the compound for the manufacture of a medicament for treating or for preventing thrombin mediated diseases.Type: GrantFiled: August 6, 2007Date of Patent: October 30, 2012Assignee: MSD Oss B.V.Inventors: Robert Gilfillan, David Jonathan Bennett
-
Patent number: 8291910Abstract: An intrauterine system (1) for the retention of a biologically active compound within the uterus of a female mammal is formed by a frame (16) defining an interior space (20) for receipt of a deposit of the compound (22). The frame has an open structure (18) allowing access to a substantial part of an outer surface of the deposit and the deposit has a rate controlling structure that controls a rate of release of the compound within the Uterus. Retention elements (6) are provided on the frame for retaining the frame within the uterus.Type: GrantFiled: November 7, 2008Date of Patent: October 23, 2012Assignee: MSD Oss B.V.Inventors: Wouter de Graaff, Harm Veenstra, Titia Martine Truce Mulders
-
Publication number: 20120245109Abstract: The present invention relates compounds of the formula (I) oligosaccharide-spacer-A ??(I), wherein the oligosaccharide is a negatively charged oligosaccharide residue comprising two to twenty five monosaccharide units, the charge being compensated by positively charged counterions, and wherein the oligosaccharide residue is derived from an oligosaccharide which has (AT-III mediated) anti-Xa activity per se; the spacer is an essentially pharmacologically inactive flexible linking residue having a chain length of 10 to 70 atoms; A is the residue —CH[NH—SO2—R1][CO—NR2—CH(4-benzamidine)-CO—NR3R4], wherein R1 is phenyl, naphthyl, 1,2,3,4-tetrahydronaphthyl, (iso)quinolinyl, tetrahydro(iso)quinolinyl, 3,4-dihydro-1H-isoquinolinyl, chromanyl or the camphor group, which groups may optionally be substituted with one or more substituents selected from (1-8C)alkyl or (1-8C)alkoxy; and wherein R2 and R3 are independently H or (1-8C)alkyl; R4 is (1-8C)alkyl or (3-8C)cycloalkyl; or R3 and R4 together with the nitrogeType: ApplicationFiled: April 4, 2012Publication date: September 27, 2012Applicant: MSD OSS B.V.Inventors: Martin DE KORT, Constant Adriaan Anton VAN BOECKEL
-
Patent number: 8273908Abstract: Process for the preparation of a compound of general formula (II) wherein R1 and R2 independently are hydrogen or a hydroxy- or hydrocarbyl group; or wherein R1 and R2 together are a double bonded oxygen; R3 is hydrogen; R?4 is a nitrobenzophenone group; and R5 and R6 independently are hydrogen or a hydroxy- or hydrocarbyl group; from a compound of general formula (I) wherein, R1, R2 R3, R5 and R6 are as defined above and R4 is hydrogen; wherein the compound of formula (I) is reacted under alkaline conditions with 2-chloro-5-nitrobenzophenone in the presence of an alkanolic solvent and the compound of formula (II) is directly crystallized from this alkanolic solvent. Complex of an alkanol and a compound of general formula (II) obtainable from the above process and processes wherein the above process or complex are used.Type: GrantFiled: August 22, 2005Date of Patent: September 25, 2012Assignee: MSD Oss B.V.Inventors: Lambertus Gerardus Maria Willems, Henricus Johannes Franciscus Maas, Martin Ostendorf
-
Publication number: 20120238512Abstract: The present invention relates compounds of the formula (I) oligosaccharide-spacer-A (I), wherein the oligosaccharide is a negatively charged oligosaccharide residue comprising two to twenty five monosaccharide units, the charge being compensated by positively charged counterions, and wherein the oligosaccharide residue is derived from an oligosaccharide which has (AT-III mediated) anti-Xa activity per se; the spacer is an essentially pharmacologically inactive flexible linking residue having a chain length of 10 to 70 atoms; A is the residue —CH[NH—SO2—R1] [CO—NR2—CH(4-benzamidine)-CO—NR3R4], wherein R1 is phenyl, naphthyl, 1,2,3,4-tetrahydronaphthyl, (iso)quinolinyl, tetrahydro(iso)quinolinyl, 3,4-dihydro-1H-isoquinolinyl, chromanyl or the camphor group, which groups may optionally be substituted with one or more substituents selected from (1-8C)alkyl or (1-8C)alkoxy; and wherein R2 and R3 are independently H or (1-8C)alkyl; R4 is (-8C)alkyl or (3-8C)cycloalkyl; or R3 and R4 together with the nitrogen atom tType: ApplicationFiled: April 4, 2012Publication date: September 20, 2012Applicant: MSD OSS B.V.Inventors: Martin De Kort, Constant Adriaan Anton Van Boeckel
-
Patent number: 8258293Abstract: The present invention relates to tetrahydroquinoline derivatives having general formula I: or a pharmaceutically acceptable salt thereof, wherein R1 is formyl, (1-6C)alkylcarbonyl or (1-6C)alkylsulfonyl; R2 and R3 are H or (1-4C)alkyl; R4 is phenyl; R5 is (1-4C)alkyl; Y—X is C(O)—O, S(O)2-O, NHC(O)—O, NHC(S)—O, OC(O)—O, bond-O, C(O)—NH, S(O)2-NH, NHC(O)—NH, NHC(S)—NH, OC(O)—NH, bond-NH, NH—C(O), O—C(O), NH—S(O)2, or O—S(O)2 or Y—X is a bond; R6 is H, trifluoromethyl, (1-6C)alkyl, 1- or 2-adamantyl(1-4C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, (3-9C)heteroaryl, (3-6C)cycloalkyl, (2-6C)heterocycloalkyl, (1-4C)alkylthio(1-4C)alkyl, (6-10C)aryl(1-4C)alkyl, (3-9C)heteroaryl(1-4C)alkyl, (3-6C)cycloalkyl(1-4C)alkyl, (2-6C)heterocycloalkyl(1-4C)alkyl, R8,R9-aminocarbonyl(1-4C)alkyl, R8,R9-amino(1-4C)alkyl, R8-oxycarbonyl(1-4C)alkyl, R8-oxy(1-4C)alkyl, R8-carbonyl(1-4C)alkyl or (6-10C)aryl; R7 is H, (1-4C)alkyl, (1-4C)alkoxy, halogen, trifluoromethyl, cyano, nitro, hydroxyl; and R8 and/or R9 is H, (1-4C)alkyl, (2-4CType: GrantFiled: October 7, 2011Date of Patent: September 4, 2012Assignee: MSD OSS B.V.Inventors: Nicole Corine Renee Van Straten, Rudolf Gijsbertus Van Someren, Jurgen Schulz